Research frontiers Because of it, nearly half of prostate cancer patients may avoid excessive biopsy

The SelectMDx test is a urine-based biomarker test commonly used to predict the presence of high-grade PCa (Gleason score ≥7)

All of the data used in the study, all from the MDxHealth database, included data from all men who underwent The SelectMDx test between May 2019 and December 2020, for a total of 5157 cases

A total of 40.

Figure 1 Percentage of negative and positive Results of SelectMDx tests in different PSA groups

Due to the heterogeneity of the PCa diagnostic tool used in different countries, there are also differences in clinical parameters (age, PSA density, digital rectal examination results) and SelectMDx test results in patients across countries, which affects the number of

Figure 2 Percentage of SelectMDx test negative and positive results for different countries and validation queues

All in all, in clinical applications, if the SelectMDx test is used as a decision-making tool for selecting men for prostate biopsy, 40.
72% of unnecessary biopsies can be avoided, but this proportion may vary
depending on the patient's characteristics.

References:

Visser WCH, de Jong H, Steyaert S, et al.
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Prostate Cancer Prostatic Dis.
2022 Sep; 25(3):583-589.